Sign Up to like & get recommendations! 0
Published in 2018 at "JAMA Surgery"
DOI: 10.1001/jamasurg.2017.3787
Abstract: Importance The efficacy of anti–factor Xa (anti-Xa)–guided dosing of thromboprophylaxis after trauma remains controversial. Objective To assess whether dosing of enoxaparin sodium based on peak anti-Xa levels is associated with the venous thromboembolism (VTE) rate… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Lung cancer"
DOI: 10.1016/j.lungcan.2019.01.018
Abstract: OBJECTIVES Pemetrexed is indicated for non-small cell lung cancer and mesothelioma. Dosing is based on body surface are (BSA), while renal function is the only determinant for exposure and thus toxicity. BSA-based dosing introduces large… read more here.
Sign Up to like & get recommendations! 0
Published in 2025 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofae631.2048
Abstract: Abstract Background Vancomycin is one of the most prescribed antibiotics for hospitalized patients. Targeting an area under the curve to a minimum inhibitory concentration (AUC/MIC) ratio of 400-600 mg*hour/L has been associated with a reduction… read more here.
Sign Up to like & get recommendations! 0
Published in 2021 at "Clinical and translational science"
DOI: 10.1111/cts.13069
Abstract: Sorafenib improves outcomes in adult hepatocellular carcinoma; however, hand foot skin reaction (HFSR) is a dose limiting toxicity of sorafenib that limits its use. HFSR has been associated with sorafenib systemic exposure. The objective of… read more here.
Sign Up to like & get recommendations! 0
Published in 2020 at "Trials"
DOI: 10.1186/s13063-020-04912-z
Abstract: Background Sickle cell disease (SCD) is a severe and devastating hematological disorder that affects over 100,000 persons in the USA and millions worldwide. Hydroxyurea is the primary disease-modifying therapy for the SCD, with proven benefits… read more here.
Sign Up to like & get recommendations! 0
Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.4_suppl.423
Abstract: 423Background: 5-FU, IRI, and nab-paclitaxel (NP) are active in advanced GI cancers; the combination (FOLFIRABRAX) has not been evaluated. UGT1A1 clears SN-38, the active metabolite of IRI. UGT1A1*28 polymorphism reduces enzymatic activity and predisposes to… read more here.
Sign Up to like & get recommendations! 0
Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.3574
Abstract: 3574Background: Irinotecan is commonly used in the treatment of advanced colorectal and pancreatic cancer. The polymorphisms UGT1A1*28 (7 TA repeats) and UGT1A1*93 (SNP -3156G > A) are significantl... read more here.
Sign Up to like & get recommendations! 0
Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.e18522
Abstract: e18522 Background: Imatinib is a mainstay of treatment for patients with chronic myeloid lymphoma (CML). Exposure-response relationships have been demonstrated and trough levels between 800 and 1000 ng/ml are usually associated with Major Molecular Response… read more here.
Sign Up to like & get recommendations! 2
Published in 2023 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2023.1184523
Abstract: Fluoropyrimidines are chemotherapeutic agents widely used for the treatment of various solid tumors. Commonly prescribed FPs include 5-fluorouracil (5-FU) and its oral prodrugs capecitabine (CAP) and tegafur. Bioconversion of 5-FU prodrugs to 5-FU and subsequent… read more here.